Antibodies to actin have been difficult to obtain, and this can be attributed to the high conservation of primary sequence throughout evolution (see reference 7). To date, most antiactin sera have been produced by animals immunized with denatured actins : by SDS treatment (19) , by precipitation with alum (14) , by chemical cross-linking and modification with glutaraldehyde (12) , or by incubation of G-actin at 4°C for at least a week (36) . In general, the sera obtained have been of low titer and contain low concentrations of specific antibody. Despite these limitations, polyclonal sera have been of use as reagents for localizing actin-containing structures in cells using immunofluorescence techniques (19) . The broad cross-reactivities ofthese sera with actins from diverse sources have allowed these studies to be carried out with various cell types and organisms (e.g., 10) .
With specific monoclonal antibodies one may obtain large amounts of homogeneous antibody directed against single antigenic determinants (16) . It is sometimes possible to use a weak immune response and obtain high-affinity antibodies against antigens such as actin that have traditionally proved to be poorly immunogenic . In addition, hybridoma clones producing antibodies that recognize different epitopes on the actin molecule can be selected and used to study the interac-THE JOURNAL Of CELL BIOLOGY " VOLUME 99 JULY 1984 287-295 C The Rockefeller University Press -0021-9525/84/07/0287/09 $1 .00 tion of actin with the many proteins that appear to regulate its functional organization in cells (17, 41) .
In this report, we describe the preparation and properties ofthree mouse monoclonal antibodies, Act I, Act II, and Act IV, against actin from the cellular slime mold, Dictyostelium discoideum. A preliminary report ofportions ofthis work has been presented (30) .
MATERIALS AND METHODS

Actin
Dictyostelium actin (D. actin)' was prepared by the method of Uyemura et al . (37) . A similar, though scaled-down, procedure was used to prepare [ 31 S] actin from Dictyostelium (29) .
Rabbit skeletal muscle actin was purified from acetone powders using the method of Spudich and Watt (31) with further purification by chromatography on diethylaminoethyl (DEAE) cellulose and size exclusion columns as described by Pardee and Spudich (24) . Human muscle actin wasisolated in the same way from an acetone powder prepared from thigh muscle tissue (provided by Dr. R. J. Rouse, Stanford University Medical Center).
Human nonmuscleactin used in these studies was an actin-rich extract of a human B lymphoblastoid cell line, prepared using the initial steps of the 'Abbreviations used in this paper: D . actin, Dictyostelium actin;'H-IAA, [ 'H]iodoacetic acid; RIA, radioimmune assay. procedure of Uyemura et al . (37) . Washed cells were lysed by sonication, and a high-speed supernatant fraction was prepared by centrifugation at 150,000 g for 90 min at 4°C. This was chromatographed at 4°C over a Sephadex G-150 superfine column (Pharmacia Fine Chemicals, Piscataway, NJ) . Fractions containing actin as the major band revealed by SDS PAGE were used in the antibody-binding studies. The actin was >50% of the total protein in the fraction .
Actins from Acanthamoeba castellanii, Physarum polycephalum, and human erythrocytes were the generous gifts of Dr . T . D . Pollard (The Johns Hopkins University), Dr. V . T. Nachmias (University of Pennsylvania), and Dr. S. L. Schrier (Stanford University Medical Center), respectively . D. actin was radiolabeled with ['H]iodoacetic acid ('H-IAA) as follows. Factin in F buffer (3 mM triethanolamine-HCI, pH 6 .5; 0.2 mM dithiothreitol ; 0 .5 mM ATP; 0.005% NaN 3; 100 mM KCI; 1 mM MgC12) was incubated with a 20-fold molar excess of 'H-IAA (203 mCi/mmol; New England Nuclear, Boston, MA) for 9 h at 37°C, then 14 h on ice . After a 24-h dialysis at 4°C versus two changes of F buffer, the labeled actin was sedimented twice at 30 psi, 20 min in an Airfuge (Beckman Instruments, Inc ., Palo Alto, CA) and finally resuspended in F buffer at 2 mg/ml. The efficiency of labeling approached I mol of iodoacetate per mol of actin .
Monoclonal Antibody Production
The strategy and basic methods have been described (25) . D . actin at 5 mg/ ml in F buffer was diluted to I mg/ml with PBS and emulsified with an equal volume of Freund's complete adjuvant . Female BALB/c mice, 4-6 wk of age, were immunized subcutaneously with 100 til of this emulsion. At 30 and 60 d the mice were reimmunized with 50 ul of antigen similarly prepared using Freund's incomplete adjuvant . 1 wk after the third immunization, mice were bled from the tail and the sera obtained were tested for antiactin antibodies in an indirect solid-phase radioimmune assay (RIA). The mice were rested for 4 mo and then immunized intravenously on four consecutive days with 25-100 ul of D . actin diluted in PBS as described above. On occasion the intravenous injection failed and the antigen was then administered intraperitoneally. A similar immunization schedule was shown by Stdhli et al . (32) to increase the yield of specific hybridomas against soluble antigens. On the fifth day the spleen cells from nine immunized animals were fused with cells of the P3/NSI/ 1-Ag4-I myeloma line (NSI) (I6) as described (25) . Hybridomas were cloned using the fluorescence-activated cell sorter (Becton Dickinson Immunocytometry Systems, Mountain View, CA) as modified by Parks et al. (27) .
IgG was obtained from ascitic fluids and purified by ammonium sulfate precipitation and chromatography on Sephadex G-200 and DEAE-cellulose columns . Purified immunoglobulins were stored frozen in PBS containing 0.1 sodium azide as a preservative . F(ab')2 and F(ab) fragments were prepared by papain degradation (26) .
C4 antibody was a gift from Dr . James L . Lessard (Children's Hospital Research Foundation, Cincinnati, OH). This mouse monoclonal IgGI was made against actin isolated from chicken gizzard smooth muscle tissue (20) .
Antigen-Antibody Binding Assays SOLID-PHASE RIA : F-actin from Dictyostelium was diluted to 100-250 ug/ml in PBS N3 (PBS buffer with 0.01 % NaN3) containing 1 mM ATP, and added to the wells of 96-well polyvinylchloride U-bottom microtiter plates (Dynatech Laboratories, Inc ., Alexandria, VA) at 25 ul per well . Wells to be used as negative controls contained PBS N 3 with 1 % (wt/vol) BSA at 25 ul per well . After an overnight incubation at 4°C in a moist environment, antigen was removed from the wells, saved, and stored on ice . F-actin solutions were repeatedly used in the RIA for periods of up to a month . Wells were washed twice with PBS N3 containing 0 .5% BSA . The plates were incubated with the second wash for 15 min at room temperature in order to saturate all proteinbinding sites. Appropriate dilutions of monoclonal antibodies were added to the wells and incubated for 2-4 h at room temperature, after which the wells were washed three times with PBS N 3 containing 0 .5% BSA . 300,000 cpm (-0 .03 ug) of "I-F(ab')2 rabbit anti-mouse IgG in 25 ul of PBS with 0.5% BSA were added to each well and incubated for 1-2 h at room temperature . After four washes with PBS N3 containing 0 .5% BSA, the wells were cut from the plates using a hot wire, and assayed for radioactivity in a Beckman Gamma 4000 (Beckman Instruments Inc., Mountain View, CA) .
FORMATION AND ANALYSIS OF IMMUNE COMPLEXES WITH M O N O M E R I C A C T I N : "S-labeled F-actin was centrifuged for 20 min at 30 psi in an Airfuge. The pellet was resuspended in G buffer (3 mM triethanolamine-HCI, pH 7 .5 ; I mM ATP; 0 .2 mM dithiothreitol; 0 .005% NaN3 ) containing 0.1 % (wt/vol) BSA by sonication for 10 s on ice with a Kontes Microultrasonic Cell Disruptor (Kontes Glass Co ., Vineland, NJ) fitted with a 4.5-in probe at a power setting of 8 (9.9 W, 25 kHz). After depolymerization of the 288 THE JOURNAL OF CELL BIOLOGY " VOLUME 99, 1984 actin on ice for 120 min, the solution was clarified by centrifugation for 60 min at 30 psi in an Airfuge . The concentration of actin monomers in the supernatant was determined by assaying an aliquot for radioactivity and spectrophotometrically using the formula of Gordon et al . (11) : Concentration in mg/mI = (A 290 nm -A 320 nm)/(0.62) .
To remove aggregates, we centrifuged solutions of IgG for 30 min at 30 psi in an Airfuge . IgG concentrations were determined spectrophotometrically using the formula: Concentration in mg/m1= A 280 nm x 0 .627 .
["S]G-actin (25 mg) was incubated overnight on ice with a 10-fold molar excess of IgG (893 ug) . Control incubations contained the nonspecific IgG, X63 (16) or no added antibody. 50 u] of dextran blue 2000 (Pharmacia Fine Chemicals) at 1 mg/ml in G buffer was then added and the samples were individually applied to a 1 .5 x 75-cm column of Sephadex G-150 superfine resin (Pharmacia Fine Chemicals) in G buffer. Fractions (0.7 ml) were collected and assayed for ["S]actin by liquid scintillation counting and for absorbance at 650 rim, to locate the dextran blue which was used as a marker for the void volume of the column .
Viscometry
Actin assembly and disassembly were measured by high-shear viscometry performed at 25°C in a Cannon-Manning Semi-micro viscometer, size 100, with a buffer flow time of 65 s (Cannon Instrument Co., State College, PA). The specific viscosity (nsp) of the solution was determined from the formula: i1sp = (flow time sample -flow time buffer)/(flow time buffer) .
Proteolytic Cleavages of Actin
Protease from Staphylococcus aureus V8 (Miles Laboratories Inc ., Elkhart, IN), papain (Sigma Chemical Co., St . Louis, MO), and trypsin-N-tosyl-Lphenylalanine chloromethyl ketone (TPCK) (Worthington Biochemical Corp ., Freehold, NJ) were used to generate fragments from 'H-labeled D . actin monomer in G buffer. Cleavage with V8 protease was done in the presence of 0 .1 % SDS for 60 min at 25°C using enzyme at 1 or 2% (wt/wt) with respect to actin which was at 500 ug/ml. Papain cleavage was for 15 or 30 min at 25°C using enzyme at 1 % (wt/wt) with respect to actin . Trypsin-TPCK cleavage was for 60 min at 25°C using enzyme at 10% (wt/wt) with respect to actin . Reactions were stopped by boiling with SDS PAGE sample buffer (18) .
Hydroxylamine Cleavage of Actin
Treatment of polypeptides with hydroxylamine under denaturing conditions specifically cleaves peptide bonds between asparagine and glycine residues (3) . D. actin contains a single such bond between residues 12 and 13 (40) . Actin monomer labeled with 'H at Cys-373 at 500 ug/ml was incubated in 200 mM K2C03; 2 M guanidine-HCI; 1 M hydroxylamine; 1 mM ATP at pH 9.0 for 4 h at 45°C. After incubation the solution was neutralized with concentrated HCI and dialyzed overnight at 4°C versus PBS N 3 containing I mM ATP.
SDS PAGE, Immunoblotting, and Autoradiography
The system of Laemmli (18) Immunoblotting was performed as described by Towbin et al. (35) , except that all solutions in which the nitrocellulose was incubated contained 0 .1% (vol/vol) Triton X-100 and 0 .02% (wt/vol) SDS (8) . Samples were electrophoresed and the gel was cut into replicate slices . One was stained for protein with Coomassie Brilliant Blue. The other slices were washed with Laemmli (18) electrode buffer without SDS . Gel slices were then lined up on nitrocellulose paper (Schleicher & Schuell, Inc., Keene, NH) and proteins were electrophoresed onto the paper using a Trans-Blot Cell (Bio-Rad Laboratories, Richmond, CA) . One replicate blot was stained for protein with amido black (0.1 % in 45% methanol, 10% acetic acid) and then destained in 90% methanol, 2% acetic acid (28) . The other blots were sequentially incubated with solutions containing BSA (1 h at 37°C) and then either antiactin antibody or control immunoglobulin (X63) (7 .5 ug/ml IgG for 14-16 h at room temperature with gentle rotation). After extensive washing with buffer and buffer containing 0.5 M NaCl, the papers were incubated for 2 h at room temperature in a solution containingRochester, NY) at -70°C using a Cronex Intensifying Screen (Dupont Co ., Wilmington, DE).
Coomassie Blue-stained gels containing 'H-labeled proteins were prepared for autoradiographic analysisby treatment with 2,5-diphenyloxazole in DMSO according to the procedure of Bonner and Laskey (4). Treated gels were dried onto filter paper and autoradiographed as above.
RESULTS
Monoclonal Antibodies against D. Actin'
The sera from mice immunized with D. actin showed specific binding to D. actin in a solid-phase RIA . When compared with sera from unimmunized mice, a specific titer of about 1 in 1,000 was detected. Specific binding to rabbit skeletal muscle actin was detected but was very weak compared to D. actin . Spleen cells from nine immunized mice were individually fused with NS1 myeloma cells and plated out into a total of 32 24 -well plates without feeder cells. In eight plates no growth of hybrid cells was seen. Vigorous growth was seen in about one-third ofthe wells ofthe remaining plates and 140 culture supernatants were tested for antibodies against actin. Of these 29 gave binding that was greater than twice the background value. On subculture, four of the 29 retained activity, and three were subsequently cloned to give hybridomas Act I, Act II, and Act IV. All three monoclonal antibodies were IgG l as shown by RIA using radioiodinated goat anti-mouse isotype specific IgG as the secondstep reagents. As actin is known to have significant affinity for a wide range of proteins including immunoglobulin, it was important to show that the binding of the monoclonal antibodies was not a low-affinity "nonspecific" interaction . This interaction has been characterized by Fechheimer et al. (9) and probably involves the Ig constant region. The following experiments showed this was unlikely as (a) all three antibodies bound to D. actin but only very weakly to rabbit skeletal muscle actin, (b) control IgGI with specificity for human leukocyte antigen molecules gave no binding to actin in the RIA, (c) soluble D. actin but not rabbit actin could completely block antibody binding to solid-phase D. actin in the RIA, (d) no inhibition of monoclonal anti-human leukocyte antigen-binding to solid-phase human leukocyte antigens by D. actin was detected, and (e) the Act antibodies, but not control IgGI, in conjunction with rabbit anti-mouse IgG and S. aureus bacteria quantitatively precipitated D. actin from solution . At this point, each hybridoma was used to generate an ascitic fluid from which the immunoglobulin was purified . Two topographically distinct epitopes are recognized by the three monoclonal antibodies . The binding to D . actin of mixtures of antibodies in a solid-phase RIA under conditions of antibody saturation (25 ug/ml) . In A the binding of Act I (0) and Act IV (A) alone are compared with Act I + Act IV (9) . B shows the binding of Act II (0), Act IV (A), Act II + Act IV (0) . F(ab)2 fragments were used to reduce the size of the antibody probes and eliminate nonspecific binding of actin to the Fc region . 125 1-F(ab')2 rabbit anti-mouse IgG was added at 250,000 dpm/well (0 .6 Ag) .
antibodies could simultaneously bind to the same actin molecule. To reduce steric hindrance and nonspecific interaction between actin and the Fc region, F(ab)2 fragments were used. Fig. 1 A shows clearly that Act I and Act II antibodies can bind to D. actin at the same time. In contrast, Act II and Act IV do not show this additive effect (Fig. 1 B) . These results suggest that Act II and Act IV recognize a closely related site on the actin molecule that is topographically separate from that recognized by Act I. In similar experiments, Act I and Act IV also showed the additive binding behavior. The results of competition assays, in which dilutions of nonradioactive Act antibodies were tested for their capacity to inhibit the binding of radioactive Act antibodies to D. actin, led to the same conclusions . Act l, Act 11, and Act IV Bind to Monomeric Actin Analytical size exclusion column chromatography was used to show that Act I, Act II, and Act IV bound actin monomers in solution with high affinity. These results also further substantiated the combining site specificity ofthe antibodies. Fig.  2 presents elution profiles of "S-labeled actin monomer preincubated with Act I antibody or with the X63 antibody as a negative control. Actin monomer alone ( Fig. 2A) or actin monomer preincubated with X63 (Fig. 2B ) eluted as a single broad peak within the included volume of the column . In contrast, when actin monomer was preincubated with the Act I monoclonal antibody, its elution position shifted markedly to a narrow peak between tubes 30 and 40, close to the elution position of the dextran blue (Fig. 2 C) . Similar results were obtained with Act II and Act IV. Therefore, in the presence of Act I, Act II or Act IV monomeric actin chromatographs as if it were in a high molecular weight complex, i.e., bound to the antibody. The sharpness of the complex peak and the lack of a peak due to free actin monomer show that the interaction between actin monomer and each monoclonal antibody is ofhigh functional affinity (--10' M-'). From these experiments one cannot determine if the stability of the immune complex is purely a result of the affinity between one antibody combining site and one actin molecule, or if closed trimolecular complexes between one IgG and two actin molecules are formed in which actin-actin interactions contribute .
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Electron Microscopy O 5 Samples placed on carbon-coated grids were negatively stained with I 0 aqueous uranyl acetate (13) and were observed and photographed using a Philips EM 201 (Philips Electronic Instruments, Inc., Mahwah, NJ) at 80 kV under conventional operating conditions. Column Fraction Number 1,500 ipoo 500 0 400 800 1200 1ßO0 2,000 0 400 800 1200 11500 2p00
Time of Polymerization (s) FIGURE 3 Effects of antiactin monoclonal antibodies on the polymerization of actin monomers into filaments . In these experiments, the polymerization of monomeric actins was followed with time by high-shear viscometry . Antibodies were added to the actin before addition of salts that would favor polymerization . As the antibodies bound strongly to monomeric actin it was possible that they would interfere with actin polymerization to form filaments. To address this question, we used high-shear viscometry, a technique that is sensitive to filament length, to measure polymerization (15, 23) . A series of tubes containing actin monomer at 250 jug/ml in G buffer was prepared. Just before the addition of salts (100 mM KCI, 1 MM M9C12, final concentrations), which were used to initiate filament formation, antiactin antibodies were mixed with the actin solutions in various molar ratios, and assembly was followed with time. Fig. 3 shows the results of several ofthese experiments . In Fig. 3A the antibody used was Act IV. Both the rate and the extent of assembly decreased as the molar ratio of antibody increased. At one antibody per two actin monomers, assembly was completely inhibited. In the control tube, where X63 was mixed with actin monomer at a ratio of one per two actins, no effect on assembly of filaments was observed. Act I and Act II yielded identical results to those obtained with Act IV (data not shown). Fig. 3 B shows the effect of Act I on the assembly kinetics of actin from rabbit skeletal muscle. At one antibody per 10 actins there is no noticeable effect; however, assembly was markedly less complete when the ratio was one antibody per two actins . As control IgGI (X63) did not inhibit, this result shows that the monoclonal antibodies do have a low but specific affinity for rabbit muscle actin. This weak crossreactivity could not be detected by RIA (see Fig. 6 ).
The effect ofthe cross-reactive monoclonal antiactin C4 on assembly of D. actin and rabbit actin filaments was also assessed (Fig. 3 C and D) . Even when the antibody was present at a molar ratio ofone per five actins, there was no effect on the assembly of either skeletal muscle actin (Fig. 3 C) or D. actin (Fig. 3D) . No decrease in either the rate or extent of filament formation was observed. In fact, when C4 was present at one per five actins, the extent of assembly was slightly increased over the control.
Act Antibodies Reduce the Size of Preformed Actin Filaments
High-shear viscometry was also used to assess the effect of the antiactin antibodies on preformed actin filaments (Fig.  4) . When Act IV antibody was added to filaments, there was an immediate and significant drop in the viscosity of the solution. At a molar ratio of one antibody per 10 actins the reduced viscosity level was maintained with time ; at a ratio of one antibody per two actins, the viscosity continued to decrease slowly to very low levels. This suggested that antibody binding resulted in filament disruption and that, when sufficient antibody was present, all the actin could be reduced to small oligomers or monomers .
A reduction in the high-shear viscosity of a solution of actin filaments can be attributed to several factors including filament shortening, either by fragmentation or by depolymerization, and filament bundling which effectively reduces the axial ratio of the particles in solution . To try to distinguish these possibilities, we observed the effect of antibody on filaments directlyby electron microscopy ofnegatively stained specimens (Fig. 5) . In the absence of antibody (Fig. 5 a) or in the presence of X63 (Fig. 5 b) the actin filaments were long and smooth surfaced . When filaments were incubated briefly with the same amount of an Act antibody, they were seen to be reduced in size and had a coat of stain-excluding material that was presumably antibody . This indicated that antibody was inducing a fragmentation or depolymerization and not a bundling of actin filaments . To test the role of antibody bivalency, the experiment was also performed with the Fab fragment of Act II at a ratio of one fragment per two actins. In this case the filaments remained intact and were largely undecorated. It can therefore be concluded that for Act II, antibody bivalency is necessary for antibody-induced changes in the size of actin filaments.
Cross-reactions of Act l, Act ll, and Act IV The RIA was used to assess the reactions of Act I, Act II, and Act IV with six different actins . Similar patterns of crossreaction were obtained for all three antibodies and are illustrated for Act I in Fig . 6 . The antibodies bind to D . actin, but not to rabbit or human skeletal muscle actins (Fig. 6A) . Although at high antibody concentrations some binding to muscle actins was seen, this was no greater than the control where BSA was the plated antigen . In contrast, the antibodies bound actins from the lower eucaryotes Physarum and Acanthamoeba as strongly as they bound D . actin (Fig. 6B) . Nonmuscle actins from erythrocytes and a human lymphoid cell line showed no more antibody binding than the BSA control . Therefore, Act I, Act II, and Act I V recognize epitopes shared by actins from lower eucaryotes, but not by actins from higher organisms, whether they are of the a-(skeletal muscle) or ß-and y-(Nonmuscle) isotypes . In contrast, to Act I, Act II, and Act IV, the C4 monoclonal antibody (Fig. 6C ) bound equivalently to D . actin and rabbit skeletal muscle actin .
Immunoblot Analysis of Actin-Antibody Reactions
Protein immunoblotting can be a useful method for localizing epitopes inasmuch as it uses the analytical potential of SDS PAGE. Act I, Act II, and Act IV were therefore tested for reactivity against D. actin in the immunoblot procedure. Only Act I gave a strong specific reaction (Fig. 7) . The minor reaction seen with Act IV in Fig . 7 was not considered significant inasmuch as the protein standards, phosphorylase b (94 kD) and carbonic anhydrase (30 kD), showed reactions of similar magnitude . The mammalian actin preparations that showed no cross-reactivity in the RIA in Fig. 6 also showed no specific reaction with Act I on immunoblotting . The reaction of Act I with D . actin by immunoblotting was subsequently used to localize a region on the D. actin molecule required for Act I binding.
Localization of a Site on Actin Required for Act I Binding
The strategy was to generate actin fragments and examine their reactivity with Act I by immunoblotting. The carboxy terminal region was specifically labeled at Cys-373 with 3H-IAA, to provide a known positional marker. Fragments which retained the 3H label were designated as having retained the carboxyl terminal and were therefore lacking an amino terminal segment. (3 and 4) , Act II (5 and 6), Act IV (7 and 8) or X63 (9 and 10) antibodies followed by "'I-F(ab')z rabbit anti-mouse IgG ; Lanes 11 and 12, amido black-stained nitrocellulose blot demonstrating efficient protein transfer.
age resulting in release of label at Cys-373 in a Lys-Cys-Phe tripeptide. As shown in Fig . 8 , all of the radioactivity was lost on tryptic digestion although the mobility of the actin was not noticeably changed . This strongly suggests that the 3H label is indeed attached to the actin at Cys-373, because only a minor cleavage, too small to be seen as a change in electrophoretic mobility, was sufficient to remove this label .
CLEAVAGE WITH PROTEASE FROM S . AUREUS V8 :
['H]D. actin was digested with different amounts of V8 protease from S. aureus and the fragments were analyzed by SDS PAGE and either Act I blotting or autoradiography to determine which fragments retained Cys-373 . As shown in lanes 3 and 4 of Fig. 9 a, a number of discrete fragments were generated from D. actin . Six major fragments are labeled 1-6 in Fig . 9 a. The immunoblot (Fig. 9a, lanes 7 and 8) shows that fragments l, 2, 3, and 5 react with Act 1. The 3H autoradiogram shows that only fragments 4 and 6 retained the carboxyl terminus and could therefore be localized within the molecule . Cleavage from the COON terminus did not result in the loss of Act I reactivity as evidenced by fragments 1, 2, 3, and 5 . Cleavage from the NHZ terminus resulted in the loss of Act I reactivity as evidenced by fragments 4 and 6 . Fragment 4 is the largest without Act I reactivity and has an apparent molecular weight of 25,000 . Therefore, the COOH terminal 25 kD of D. actin are not sufficient for Act I reactivity and this implies that the NHZ terminal 18 kD are important for Act I binding . From examination of the sequence of D. actin, one can postulate that the cleavage that generates fragment 4 is the Glu-Gly bond between residues 167 and 168. This assumes that the V8 protease cleaves specifically at the carboxyl side of glutamic acid residues . CLEAVAGE WITH PAPAIN : ['H]D . actin was treated with papain and the pattern of fragmentation was analyzed as described in the previous section . The results are in agreement with those obtained with V8 protease . The largest fragment containing the carboxyl terminus that did not react with Act I was fragment 1, of apparent molecular weight 37,000 (Fig. 96) . This extends the analysis made with V8 protease fragment 4 and suggests that the NH Z terminal 6 kD of D . actin are required for binding of Act I in this system . CLEAVAGE WITH HYDROXYLAMINE : [ 3 H]D . actin was treated with hydroxylamine and the fragments assayed for retention of Cys-373 and for Act I binding. After treatment a new species was seen that had a mobility compatible with the removal of a small number of amino acids from the actin (Fig. 10, lane 4) . The corresponding autoradiogram in Fig.  10 , lane 12 shows that this new species retains the carboxyl terminus. This is consistent with cleavage at the asparagylglycine bond between residues 12 and 13 as previously described (3, 34) . The fragment that has lost the first 12 NHZ terminal amino acids retains reactivity with Act I as shown in Fig. 10 , lane 8 . This result shows that these residues are not necessary for Act I binding . FIGURE 10 The NH2-terminal 12 residues of D. actin are not required for Act I binding . 'H-labeled D. actin was treated with hydroxylamine and the fragments were analyzed by SDS PAGE, autoradiography, and immunóblotting. Replicate sets of four lanes show Coomassie Blue staining for protein (lanes 1-4) , immunoblot with Act I and 125 1-F(ab')2 rabbit anti-mouse IgG (lanes [5] [6] [7] [8] , and autoradiogram of gel to detect the 'H label at residue 373 in the COOH terminal region (lanes 9-12) . Lanes 1, 5, and 9 contain protein standards with molecular weights (x10-') as shown ; lanes 2, 6, and 10 contain untreated actin ; lanes 3, 7, and 11, "mock"-treated actin, and lanes 4, 8, and 12, hydroxylamine-treated actin . "Mock" treatment was identical to hydroxylamine treatment except that hydroxylamine was omitted . The upper arrow on the right indicates the position of intact actin, the lower arrow the position of the hydroxylamine-generated fragment of an apparent molecular weight of 42,000 .
Summary of Localization of the Act 1 Binding Region on D . Actin Fig. 11 summarizes the analysis of actin fragments for Act I binding. Cleavage of actin with V8 protease results in the formation of a 25-kD fragment of actin that has retained the carboxyl terminus, but has lost the ability to bind Act I antibody. Cleavage of actin with papain produces a fragment with similar properties, but with a molecular weight of 37,000. These results suggest that the amino acids necessary for antibody recognition of the actin reside in the amino terminal 50 (approximately) residues . However, the hydroxylamine result indicates that the initial 12 amino terminal residues are not required for antibody recognition of the actin . In summary, amino acids from 13 through -50 in the D . actin sequence are required for binding of the Act I antibody.
The amino acid sequences of actins were compared to identify substitutions that correlated with the species specificity of Act 1 (6, 22, 38, 39, 40) . In particular, a search was made for residues that were shared by actins from the lower eucaryotes and substituted in mammalian actins . Within the sequence 13-50, there is a single residue that satisfies this criterion . At position 41 the three lower eucaryotes have threonine whereas mammalian actins have glutamine . This suggests that threonine 41 is a critical residue for formation of the Act I antigenic site . As Act I reacts strongly in immunoblotting, it is probable that threonine 41 interacts directly with the Act I combining site . However, the other possibility that the substitution at position 41 causes a conformational and antigenic change, at a topographically distinct site that binds Act I, is not ruled out.
294 THE JOURNAL OF CELL BIOLOGY " VOLUME 99, 1984 DISCUSSION Hyperimmunization of BALB/c mice with D . actin results in a significant immune response that was utilized to make three monoclonal antibodies, Act I, Act II, and Act IV. The specificity of these antibodies reflects that of the polyclonal sera in that they were of high affinity for D. actin and of low affinity for rabbit skeletal muscle actin . All three antibodies bound similarly to actins of three lower eucaryotic organisms, Dictyostelium, Physarum, and Acanthamoeba, but did not bind to a-, Q-, or y-actins from human or rabbit . This species specificity correlates with the extent of amino acid sequence homology between the various actins (6, 22, 38, 39, 40) . Lessard et al. (20) prepared two murine monoclonal antibodies, C4 and B4, against chicken gizzard actin . The C4 antibody appears to be broadly specific, whereas the B4 antibody reacts strongly only with muscle actins . Caceres et al . (5) described two monoclonal antibodies against quail breast actin (QAB1, QAB2), which do not discriminate between vertebrate actins. Thus highly specific and broadly specific monoclonal antibodies can be prepared against actins from diverse sources .
The three antibodies, Act I, Act II, and Act IV identify two topographically distinct epitopes ofthe D. actin molecule; one recognized by Act I and the other by Act II and Act IV. Analysis of D . actin fragments by immunoblotting showed that amino acids 13 to about 50 are required for Act I binding and that the threonine residue at position 41 is critically involved in forming the Act I epitope .
The effects the three antibodies have upon the properties of D. actin have so far been indistinguishable . They form stable complexes with monomeric actin which prevents the actin from polymerizing into filaments. Conversely, addition of the antibodies to preformed actin filaments causes them to become smaller. When a stoichiometric amount of antibody is added (a) to monomeric actin, polymerization is completely inhibited, and (b) to filamentous actin, the viscosity is reduced to the level of monomeric actin . These results show that the energy gained by forming complexes between antibody and actin is greater than that gained by forming actin filaments . The antibodies could interfere with filament formation either by covering or conformationally altering a site involved in actin-actin interaction, or by steric hindrance when bound to a site not involved in actin-actin interaction . The latter is a serious possibility inasmuch as an antibody molecule is about 3 Summary of the results of the experiments to localize the region on D . actin required for Act I antibody binding. three times the size ofan actin monomer . However, the results with the C4 antibody (Fig. 3 C and D) show that not all monoclonal antibodies will inhibit actin filament assembly. The mechanism by which the antibodies depolymerize filaments is not known. It could involve removal of the actin monomer pool or direct binding to the filaments resulting in fragmentation within the filament or removal of monomers from the ends. A cooperative effect between the two combining sites of the antibody appears to be involved as Fab fragments of Act II do not affect filament integrity .
A variety of circumstantial evidence suggest that the epitopes recognized by Act II and Act IV are formed by residues in the NH2 terminal region ofthe actin molecule. Combining the results of crystallographic studies with a study of proteolytic susceptibility Mornet and Ue (21) concluded that actin consists of a small NH2-terminal domain of -80 residues linked to a larger COOH-terminal domain that contains the rest of the molecule. Within the actin filament the small domains are turned "inward" and the larger domains are turned "outward" (33) . This is consistent with the conclusion ofBenjamin et al. (2) that antibodies against the NH2-terminal part ofmonomerc actin do not bind actin filaments whereas antibodies against the COOH-terminal region do. In keeping with this picture, and knowing that Act I, Act 11, and Act IV bind monomer and destroy filaments, one would postulate that all three antibodies are against epitopes of the smaller NH2-terminal domain. For Act I, there is independent evidence from the immunoblotting analysis that this is correct . Ifone assumes it is also true for Act II and Act IV, then what residues could be involved in their target epitopes? Within the actin sequence, only residues at positions 2, 5, 6, 41, 234, 295, 297, 306, 317, and 360 fulfill the criterion of being shared by Dictyostelium, Physarum, and Acanthamoeba actins and distinct from mammalian actins. Clearly, it is only the residues at positions 2, 5, 6, and 41 that could be in a smaller NH2-terminal domain. Inasmuch as Act II and Act IV are against a topographically different epitope from Act I, involvement of threonine 41 is excluded . One is thus left with glycine 2, valine 5, and glutamine 6 as the most likely residues to be involved in the epitopes recognized by Act II and Act IV.
